• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • The Personalized Cancer Vaccine Platform
      • PreVAX™
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Most Recent Publications
T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

08-2018

Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.

04-2018

In Silico and In Vitro Analysis of Interaction between Ximelagatran and Human Leukocyte Antigen (HLA)-DRB1*07:01.

04-2018

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks.

04-2018

Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies.

04-2018

Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates.

04-2018

Immunodominance in T cell responses elicited against different domains of detoxified pneumolysin PlyD1.

04-2018

Mass spectrometry-assisted identification of ADAMTS13-derived peptides presented on HLA-DR and HLA-DQ.

04-2018

Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”

02-2018

De-immunized and Functional Therapeutic (DeFT) versions of a long lasting recombinant alpha interferon for antiviral therapy

01-2018

Evaluating Immunogenicity Risk Due to Host Cell Protein Impurities in Antibody-Based Biotherapeutics

12-2017

Circulating Normal IgG as Stimulator of Regulatory T Cells: Lessons from Intravenous Immunoglobulin

12-2017

« Older Entries
Next Entries »

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

Manage Consent

This website uses cookies and similar technologies to collect information about your website experience for advertising, analytics, and other purposes as described in our Privacy Policy. 

Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}